Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Dosage Regimens: Designs and Approaches

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

Drug Control Governance: Regulatory Bodies and Their Impact

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biomarker-Based Prediction of OATP1B1 Activity in Clinical Routine-Investigating Coproporphyrins as Markers for Drug-Drug-Gene Interactions.

Clinical pharmacology and therapeutics·2026

Same author

Timing and intensity of proton pump inhibitor exposure hampers overall survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective cohort study.

Frontiers in immunology·2026

Same author

Genetic Determinants of Analgesic Responsiveness: A Focus on CYP2D6 and COMT Polymorphisms in Chronic Pain.

The Clinical journal of pain·2026

Same author

Characteristics and availability of medicine early access programs and donations in Slovenia.

The oncologist·2025

Same author

Association of Pharmacogenotyping and Patient-Reported Outcomes in Chronic Pain Management.

Health services insights·2025

Same author

Stakeholder Consensus on an Interdisciplinary Terminology to Enable the Development and Uptake of Medication Adherence Technologies Across Health Systems: Web-Based Real-Time Delphi Study.

Journal of medical Internet research·2025

Search research articles

Related Experiment Video

Updated: Jan 3, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Community pharmacist-led medication review procedures across Europe: Characterization, implementation and

Tamara Leila Imfeld-Isenegger¹, Inês Branco Soares², Urska Nabergoj Makovec³

¹Pharmaceutical Care Research Group, University of Basel, Switzerland.

Research in Social & Administrative Pharmacy : RSAP

|November 18, 2019

Summary

Community pharmacies across Europe show varied implementation of medication reviews, with simpler types like Type 1 and 2a being more common. Ongoing projects suggest future growth in these essential patient care services.

Keywords:

Community pharmacy services Europe Medication review Primary health care Remuneration Service implementation

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Experiment Videos

Last Updated: Jan 3, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Area of Science:

Pharmacy Practice
Health Services Research
Medication Management

Background:

The Pharmaceutical Care Network Europe (PCNE) established a classification system for medication reviews in 2016.
A gap exists in understanding the implementation and reimbursement of these medication review procedures across European community pharmacies.

Purpose of the Study:

To describe the types of medication review procedures implemented in European community pharmacies.
To assess the level of implementation and third-party remuneration for medication reviews across Europe.

Main Methods:

An online survey was distributed to experts in 44 European countries.
The survey characterized medication review procedures based on the PCNE classification, implementation status, and remuneration.
Data triangulation and consensus-seeking were employed to ensure data reliability.

Main Results:

Data from 34 countries (77% response rate) revealed that 55.9% offered at least one type of medication review.
Type 1 (medication history) and Type 2a (history + patient interview) reviews were most prevalent.
Only ten services/projects reported third-party remuneration, highlighting significant heterogeneity.

Conclusions:

There is substantial variation in medication review procedures, implementation, and remuneration across Europe.
Type 1 and 2a medication reviews are more feasible for community pharmacy implementation compared to Type 2b and 3.
The number of ongoing medication review projects indicates potential for future service expansion.